Despite their initial concern about UTC’s potential negative effects on the recipients, the researchers found promising results. The study in Kenya found that the assisted households increased their consumption and savings. While the families spent more for their food and food security, they did not incur any expenses on unnecessary goods or services. This study shows that a proper approach to poverty could effectively eliminate this factor as part of a solution to homelessness. Providing access to education and employment to low-income families and individuals must also be considered to combat poverty and preventing homelessness. Physical and mental health
It is not surprising that many researchers have identified that “Homelessness is closely connected to decline in physical and mental health”. Most people who use homeless shelters on a frequent basis face multiple disadvantages, such as increased prevalence of physical and mental health problems, disabilities, addiction, poverty, and discrimination. Studies have shown that homeless people have a high level of morbidity and mortality. Moreover, they suffer from a wide range of health problems, including contracting sever infectious diseases (such as tuberculosis, HIV/AIDs, and STDs), addictions, and mental illnesses. Notably, the lack of access to healthcare for homeless people adversely affects the healthcare system as well. Homeless people often obtain their care in emergency departments, partly due to their lack of adequate health insurance, especially for medications. Statistics demonstrate that they are admitted to hospital five times more than the public and stay under care much longer.
Participants and the health providers knew which treatments have been given.In Trial 2, participants who were previously successfully treated for the infection (who had HIV-1 RNA less than 50 copies/milliliter), were randomized to receive either cabotegravir/rilpivirine (for the first four weeks they received tablets) or to remain on the same therapy for additional 44 weeks. Participants and the health providers knew which treatments have been given.In October 2020, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended the granting of a marketing authorization for rilpivirine and cabotegravir, to be used together for the treatment of people with human immunodeficiency virus type 1 (HIV-1) infection. The two medicines are the first antiretrovirals that come in a long-acting injectable formulation. This means that instead of daily pills, people receive intramuscular injections monthly or every two months. Rilpivirine and cabotegravir were approved for medical use in the European Union in December 2020, as two separate medications.In January 2021, the U.S. Food and Drug Administration (FDA) granted the approval of Cabenuva to ViiV Healthcare.The combination was approved for medical use in Australia in February 2021. References
External links
"Cabotegravir". Drug Information Portal. U.S. National Library of Medicine. "Rilpivirine". Drug Information Portal. U.S. National Library of Medicine.